腹膜透析对尿毒症患者血浆Hcy和血清NO的影响及对心血管并发症防治价值的探讨
|
摘要
目的:同型半胱氨酸(homocysteine,Hcy)是一种的非必需氨基酸,肾脏是其重要的代谢场所。慢性肾功能不全患者血浆Hcy水平常明显升高,且血浆Hcy升高程度与肾功能的下降相平行。Hcy被认为是心血管疾病的独立危险因素,高同型半胱氨酸血症与终末期肾脏病(end stage renal kidney,ESRD)患者心血管疾病的发生率和病死率有关。一氧化氮(nitro oxide,NO)是评价血管内皮功能的一个重要指标,NO在慢性肾功能不全的发生、发展过程中的地位目前尚未明确,且ESRD时Hcy与NO的关系尚不清楚。本实验通过对尿毒症组和腹膜透析组患者血浆、腹透液Hcy和血清、腹透液NO水平的检测,评价腹膜透析对尿毒症患者血浆Hcy和血清NO的影响,探讨腹膜透析在防治ESRD心血管并发症中的作用。
方法:选取尿毒症患者60例,分为尿毒症组和持续性非卧床腹膜透析组(continuous ambulatory peritoneal dialysis,CAPD组),各30例;健康体检者20例为对照组。三组间年龄性别相匹配(见表1-2)。两实验组患者近一个月内均无显性水肿,临床状况稳定,无腹腔内和其他部位感染,无严重的心力衰竭、胃肠道出血、活动性肝病、肿瘤、创伤及手术等合并症。对照组均经体检排除感染、高脂血症、高血压、糖尿病、心脑血管疾病及肝肾疾病。留取各组受试者的血浆和血清,测定Hcy、NO和其他生化指标,其中高压液相色谱技术测定血浆和腹透液Hcy水平,硝酸酶还原法测定血清和腹透液NO水平。
结果:对照组血浆Hcy水平为8.73±1.20μmol/L,尿毒症组Hcy水平为45.10±15.65μmol/L,CAPD组为35.96±16.86μmol/L,腹透液的Hcy水平为9.76±7.25umol/L。统计学分析后,尿毒症组和CAPD组的Hcy均高于对照组(P＜0.01),尿毒症组Hcy高于CAPD组(P＜0.05)。尿毒症组血压正常患者血浆Hcy水平为32.17±7.87μmol/L,尿毒症组伴高血压患者血浆Hcy水平为51.56±14.57μmol/L。两组间比较差异有统计学意义(P＜0.01)。CAPD组血压正常患者血浆Hcy水平为23.97±7.42μmol/L,CAPD组伴有高血压患者血浆Hcy水平为41.96±17.16μmol/L。两者比较差异有统计学意义(P＜0.01)。对照组血清NO水平为53.72±11.51μmol/L,尿毒症组患者血清NO水平为182.78±45.32μmol/L,CAPD组血清NO水平为171.60±33.55μmol/L,腹透液的NO水平为120.29±41.80μmol/L。进行统计学分析后,尿毒症组和CAPD组的血清NO均高于对照组(P＜0.01)。CAPD组的血清NO水平低于尿毒症组,但是两组间比较差异无统计学意义(P＞0.05)。
结论:尿毒症组和CAPD组血浆Hcy水平均高于对照组,然而CAPD组低于尿毒症组。尿毒症组和CAPD组伴有高血压者的血浆Hcy高于血压正常者。ESRD患者血浆Hcy与年龄、高血压成正相关关系。尿毒症组和CAPD组血清NO水平均高于对照组。CAPD组血清NO水平低于尿毒症组,但是差异无统计学意义。腹膜透析可以清除尿毒症患者的血浆Hcy,从而降低尿毒症患者的高同型半胱氨酸血症,腹膜透析也可以清除尿毒症患者的血清NO,但是两组之间比较无统计学意义。近年来的研究认为慢性肾功能衰竭的患者Hcy的升高是发生心血管系统疾病的独立危险因素之一。机体内过量的NO也会造成组织细胞的损伤。高同型半胱氨酸血症在尿毒症患者和腹膜透析患者中普遍存在,对于其高同型半胱氨酸血症和高NO血症的治疗有待于进一步的研究。
Objetcive:Homocysteine(Hcy) is a non-essential amino acid.Kidney is an important metabolism place.In the recent years,homocysteine is considered as an independent risk factor of cardiovascular disease.The plasma homocysteine level is often significantly higher in the patients of chronic renal failure.And the increased plasma Hcy level is parallelled with the renal function decline.Homocysteine is considered an independent risk factor of cardiovascular disease.Hyperhomocys-teinemia is related to the cardiovascular disease incidence and mortality of the patients of the end-stage renal disease(ESRD).Nitric oxide(NO) is an important index of the evaluation of endothelial function.It is not yet clear that NO plays a part in the occurrence and development of chronic renal failure.And the relationship between Hcy and NO is not clear in the ESRD patients.This experiment is to explore the effect of peritoneal dialysis on plasma homocysteine and nitric oxide(NO) level of uremic patients,through detecting the serum Hcy and NO levels of the the uremia group and peritoneal dialysis group.To discuss the role of peritoneal dialysis on the prevention and treatment of cardiovascular complications in the ESRD patients.
Methods:The uremia patients were collected.They were divided into the uremia group and the continuous ambulatory peritoneal dialysis(CAPD) group.The each group was 30 cases.The healthy adult were 20 cases.And they were considered as the control group.The age and gender among the three groups were matched.The patients of uremia group and CAPD group had not dominant edema,peritoneal infection and other infections,and clinical situation was stable.They had not serious heart failure, gastrointestinal bleeding,active liver disease,cancer,trauma and surgery factors.The control group had been considered by the medical examination to exclude infection, hyperlipidemia,hypertension,diabetes,cardiovascular,cerebrovascular diseases and liver and kidney disease.The plasma and serum of each group were colleted.The Hcy levels of the plasma and peritoneal dialysis fluid were measured by high performance liquid chromatography analysis.The NO levels of the serum and peritoneal dialysis fluid were measured by enzyme nitrate reduction.
Results:The plasma Hcy level of the control group was 8.73±1.20μmol/L.The plasma Hcy level of the uremia group was 45.10±15.65μmol/L.The plasma Hcy level of the CAPD group was 35.96±16.86μmol/L.The Hcy level of peritoneal dialysis fluid was 9.76±7.25 umol/L.After the statistical analysis,the Hcy of the uremia group and CAPD group were higher than that of the control group(P＜0.01). The Hcy of the uremia group was higher than that of the CAPD group(P＜0.05).The plasma Hcy level of the uremia group with normal blood pressure was 32.17±7.87μmol/L,but the plasma Hcy level of the uremia group with hypertension was 51.56±14.57μmol/L.The differences between the two groups were statistically significant(P＜0.01).The plasma Hcy level of the CAPD group with normal blood pressure was 23.97±7.42μmol/L,but the plasma Hey level of the CAPD group with hypertension was 41.96±17.16μmol/L.The differences between the two groups were statistically significant(P＜0.01).The serum NO level of the control group was 53.72±11.51μmol/L.The serum NO level of the uremia group was 182.78±45.32μmol/L.The serum NO level of the CAPD group was 171.60±33.55μmol/L.The NO level of peritoneal dialysis fluid was 120.29±41.80μmol/L.After the statistical analysis,The NO level of uremia and CAPD group group were higher than that of the control group(P＜0.01).The NO level of the CAPD group was lower than that of the uremia group,but comparison between the two groups was no significant difference(P＞0.05).
Conclusions:Compared with the control group,the plasma Hcy levels of the uremia group and CAPD group were higher than that of the control group.But the Hey level of CAPD group was lower than that of the uremia group.The plasma Hcy level of the uremia group and CAPD group with hypertension was higher than that with normal blood pressure.The plasma Hcy level of the ESRD patients was positively correlated with age and hypertension.Compared with the control group,the serum NO levels of uremia group and CAPD group were statistically significant,and were higher than that of the control group.And the NO level of the CAPD group was lower than that of the uremia group.But the difference between the two groups was no statistical significance.Peritoneal dialysis can remove plasma homocysteine of the uremic patients,and lower the hyperhomocysteinemia of the uremia patients.Peritoneal dialysis can remove serum NO of the uremic patients,but the difference between was no statistical significance.In the recent years,some reseraches suggested that the Hcy level of the chronic renal failure patients was an independent risk factor for cardiovascular disease.The excessive NO levels of the body were damaged to tissue and cells.Hyperhomocysteinemia was prevalent in patients of the uremia and peritoneal dialysis patients.The treatment for its hyperhomocysteinemia and the higher NO levels needs further study.
方法:选取尿毒症患者60例,分为尿毒症组和持续性非卧床腹膜透析组(continuous ambulatory peritoneal dialysis,CAPD组),各30例;健康体检者20例为对照组。三组间年龄性别相匹配(见表1-2)。两实验组患者近一个月内均无显性水肿,临床状况稳定,无腹腔内和其他部位感染,无严重的心力衰竭、胃肠道出血、活动性肝病、肿瘤、创伤及手术等合并症。对照组均经体检排除感染、高脂血症、高血压、糖尿病、心脑血管疾病及肝肾疾病。留取各组受试者的血浆和血清,测定Hcy、NO和其他生化指标,其中高压液相色谱技术测定血浆和腹透液Hcy水平,硝酸酶还原法测定血清和腹透液NO水平。
结果:对照组血浆Hcy水平为8.73±1.20μmol/L,尿毒症组Hcy水平为45.10±15.65μmol/L,CAPD组为35.96±16.86μmol/L,腹透液的Hcy水平为9.76±7.25umol/L。统计学分析后,尿毒症组和CAPD组的Hcy均高于对照组(P＜0.01),尿毒症组Hcy高于CAPD组(P＜0.05)。尿毒症组血压正常患者血浆Hcy水平为32.17±7.87μmol/L,尿毒症组伴高血压患者血浆Hcy水平为51.56±14.57μmol/L。两组间比较差异有统计学意义(P＜0.01)。CAPD组血压正常患者血浆Hcy水平为23.97±7.42μmol/L,CAPD组伴有高血压患者血浆Hcy水平为41.96±17.16μmol/L。两者比较差异有统计学意义(P＜0.01)。对照组血清NO水平为53.72±11.51μmol/L,尿毒症组患者血清NO水平为182.78±45.32μmol/L,CAPD组血清NO水平为171.60±33.55μmol/L,腹透液的NO水平为120.29±41.80μmol/L。进行统计学分析后,尿毒症组和CAPD组的血清NO均高于对照组(P＜0.01)。CAPD组的血清NO水平低于尿毒症组,但是两组间比较差异无统计学意义(P＞0.05)。
结论:尿毒症组和CAPD组血浆Hcy水平均高于对照组,然而CAPD组低于尿毒症组。尿毒症组和CAPD组伴有高血压者的血浆Hcy高于血压正常者。ESRD患者血浆Hcy与年龄、高血压成正相关关系。尿毒症组和CAPD组血清NO水平均高于对照组。CAPD组血清NO水平低于尿毒症组,但是差异无统计学意义。腹膜透析可以清除尿毒症患者的血浆Hcy,从而降低尿毒症患者的高同型半胱氨酸血症,腹膜透析也可以清除尿毒症患者的血清NO,但是两组之间比较无统计学意义。近年来的研究认为慢性肾功能衰竭的患者Hcy的升高是发生心血管系统疾病的独立危险因素之一。机体内过量的NO也会造成组织细胞的损伤。高同型半胱氨酸血症在尿毒症患者和腹膜透析患者中普遍存在,对于其高同型半胱氨酸血症和高NO血症的治疗有待于进一步的研究。
Objetcive:Homocysteine(Hcy) is a non-essential amino acid.Kidney is an important metabolism place.In the recent years,homocysteine is considered as an independent risk factor of cardiovascular disease.The plasma homocysteine level is often significantly higher in the patients of chronic renal failure.And the increased plasma Hcy level is parallelled with the renal function decline.Homocysteine is considered an independent risk factor of cardiovascular disease.Hyperhomocys-teinemia is related to the cardiovascular disease incidence and mortality of the patients of the end-stage renal disease(ESRD).Nitric oxide(NO) is an important index of the evaluation of endothelial function.It is not yet clear that NO plays a part in the occurrence and development of chronic renal failure.And the relationship between Hcy and NO is not clear in the ESRD patients.This experiment is to explore the effect of peritoneal dialysis on plasma homocysteine and nitric oxide(NO) level of uremic patients,through detecting the serum Hcy and NO levels of the the uremia group and peritoneal dialysis group.To discuss the role of peritoneal dialysis on the prevention and treatment of cardiovascular complications in the ESRD patients.
Methods:The uremia patients were collected.They were divided into the uremia group and the continuous ambulatory peritoneal dialysis(CAPD) group.The each group was 30 cases.The healthy adult were 20 cases.And they were considered as the control group.The age and gender among the three groups were matched.The patients of uremia group and CAPD group had not dominant edema,peritoneal infection and other infections,and clinical situation was stable.They had not serious heart failure, gastrointestinal bleeding,active liver disease,cancer,trauma and surgery factors.The control group had been considered by the medical examination to exclude infection, hyperlipidemia,hypertension,diabetes,cardiovascular,cerebrovascular diseases and liver and kidney disease.The plasma and serum of each group were colleted.The Hcy levels of the plasma and peritoneal dialysis fluid were measured by high performance liquid chromatography analysis.The NO levels of the serum and peritoneal dialysis fluid were measured by enzyme nitrate reduction.
Results:The plasma Hcy level of the control group was 8.73±1.20μmol/L.The plasma Hcy level of the uremia group was 45.10±15.65μmol/L.The plasma Hcy level of the CAPD group was 35.96±16.86μmol/L.The Hcy level of peritoneal dialysis fluid was 9.76±7.25 umol/L.After the statistical analysis,the Hcy of the uremia group and CAPD group were higher than that of the control group(P＜0.01). The Hcy of the uremia group was higher than that of the CAPD group(P＜0.05).The plasma Hcy level of the uremia group with normal blood pressure was 32.17±7.87μmol/L,but the plasma Hcy level of the uremia group with hypertension was 51.56±14.57μmol/L.The differences between the two groups were statistically significant(P＜0.01).The plasma Hcy level of the CAPD group with normal blood pressure was 23.97±7.42μmol/L,but the plasma Hey level of the CAPD group with hypertension was 41.96±17.16μmol/L.The differences between the two groups were statistically significant(P＜0.01).The serum NO level of the control group was 53.72±11.51μmol/L.The serum NO level of the uremia group was 182.78±45.32μmol/L.The serum NO level of the CAPD group was 171.60±33.55μmol/L.The NO level of peritoneal dialysis fluid was 120.29±41.80μmol/L.After the statistical analysis,The NO level of uremia and CAPD group group were higher than that of the control group(P＜0.01).The NO level of the CAPD group was lower than that of the uremia group,but comparison between the two groups was no significant difference(P＞0.05).
Conclusions:Compared with the control group,the plasma Hcy levels of the uremia group and CAPD group were higher than that of the control group.But the Hey level of CAPD group was lower than that of the uremia group.The plasma Hcy level of the uremia group and CAPD group with hypertension was higher than that with normal blood pressure.The plasma Hcy level of the ESRD patients was positively correlated with age and hypertension.Compared with the control group,the serum NO levels of uremia group and CAPD group were statistically significant,and were higher than that of the control group.And the NO level of the CAPD group was lower than that of the uremia group.But the difference between the two groups was no statistical significance.Peritoneal dialysis can remove plasma homocysteine of the uremic patients,and lower the hyperhomocysteinemia of the uremia patients.Peritoneal dialysis can remove serum NO of the uremic patients,but the difference between was no statistical significance.In the recent years,some reseraches suggested that the Hcy level of the chronic renal failure patients was an independent risk factor for cardiovascular disease.The excessive NO levels of the body were damaged to tissue and cells.Hyperhomocysteinemia was prevalent in patients of the uremia and peritoneal dialysis patients.The treatment for its hyperhomocysteinemia and the higher NO levels needs further study.
引文
[1]Boushey CJ,Beresford SA,Imenn GS,et al.JAMA,1995,274:1049-1057.
[2]Boushey CJ,Beresfard SA,Omenn GS,et al.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increasing folic acid intakes[J].JAMA,1995,274(13):1049-1057.
[3]Graham IM,Daly LE,Refaum HM,et al.Plasma homocysteine as a risk factor for vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
[4]Taylor LM Jr,DeFrang RD,Harris EJ Jr,et al.The association of elevated plasma homocyst(e)ine with progresion of symptomatic peripheral arterial disease[J].Vase Surg,1991,13(1):128-136.
[5]Danesh J,LewingtonS.Plasma homocysteine and coronary artery disease:systematic review of published epidemiological studies[J].Cardiovasc Risk,1998,5:229-232.
[6]Nyord O,Vollest SE,Refaum H,et al.Total homocysteine and canliovascular disease[J].Intern Med,1999,246:425-454.
[7]Meleady R,Graham I.Plasma homocysteine as a canliovascular riskfactor:causal,consequential,or of no consequence[J].Nutr Rev,1999,57:299-305.
[8]Moustapha A,Naso A,Nahlawi M,et al.Circulation,1998,97(2):138-141.
[9]Rysz J,Luciak M,Kedziora J,et al.Nitric oxide release in peripheral blood during hemodialysis.Kidney Int,1997,51:294-300.
[10]Wever R,Boer P,Hjjmering M,et al.Nitric oxide production is reduced is patients with chronic renal failure.Arteroseler Thromb Vasc Biol,1999,19:1168-1172.
[11]路建饶,武立群.老年慢性肾衰血液透析患者血浆同型半胱氨酸的临床研究[J].中国老年学杂志,2005,25:519-521.
[12]Selhub J.Homocysteine metabolism[J].Annu Rev Med,1999,19:217-46.
[13]Hankey GJ,eikelboom JW,Ho WK,et al.Clinical usefulness of plasma homocyteine in vascular disease[J].Med J Aust,2004,181(6):314-318.
[14]Woo KS,Chook P,Lolin YI,et al.Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans[J].Circulation,1997,96(8):2542-2544.
[15]Faraci FM,Lentz SR.Hyperhomocysteinemla.oxidative stress,and cerebral vascular dysfunction.Stroke,2004,35:345-347.
[16]Lang D,Kredan MB,Moat AJ,et al.Homocysteine induced inhibitation of endothelium dependent relaxation in rabbit Aorta.Arterioscler Thromb Vase Biol,2000,20:422-427.
[17]Frank M,Steven R.Hyperhomocysteinemia,Oxidative Stress,and Cerebral Vascular-Dysfunction.Stroke,2004,35:345-347.
[18]Dayal S Arning E,Bottiglieri T,et al.Cerebral vascular Dysfunction mediated by superoxide in hyperhomocysteinmic mice[J].Stroke,2004,35:1957-1962.
[19]Neetu T,Kara C,Mesia S.et al.Mechanisms of homocysteine-induced oxidative stress[J].Am J Physiol Heart Cire Physiol,2005,289:H2649-H2656.
[20]Heydrick SJ,Wiesia N,Thomas SR et al.L-homocysteine and L-homocysteine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells[J].Free Radic Biol Med,2004,36:632-40.
[21]Toiler GH,Agoatino RB,Jacques PF,et al.Association between incrcasccl homocysteine levels and impaired fibrinolytic potential:potential mechanism for cardiovascular risk.Thromb Haemoat,2002,88:799-804.
[22]Majors AK,Sengupta S,Jacobsen DW,et al.Upregulation of smooth muscle cell collagen production by homocysteine insight into the pathogenesis of homocystinuria.Mol Genet Metab,2002,76(2):92-99.
[23]Kartal Ozer N,Negis Y,Aytan N.Molecular mechanisms of cholesterol or homocysteine efect in the development of atherosclerosis:Role of vitamin E.Biofactovs,2003,19(1-2):63-70.
[24]Au-Yetung KK,Woo CW,Sung FL,et al.Hyperhomoeysteinemia activates nuclear factor-κ B in endothelial cells via oxidative stress.Cite Res,2004,94:28-36.
[25]张红,张平,纪元.冠心病患者超敏C反应蛋白和同型半胱氨酸水平变化的意义[J].现代检验医学杂志,2007,22(6):102-103.
[26]郑法雷,章有康,陈香美,等.肾脏病临床与进展[J].北京:人民军医出版社,2005,239-257.
[27]Brattstom L,Wilcken DEL.Homocysteine and cardiovascular disease,cause or effect[J].Am J Clin Nutr,2000,72(2):315-323.
[28]邱丽君,顾青,汪维乐,等.尿毒症患者血浆同型半胱氨酸及皮细胞功能变化的意[J].检验医学,2008,23(2):143-144.
[29]余海峰,李春胜,陈军斌,等.慢性肾功能衰竭对血浆同型半胱氨酸水平的影响[J].实用医学杂志.2005,21(3):275-276.
[30]Anwar W,Gueant JL,Abdelmouttaleb,et al.Hyperhomocystemia is related to residual glomemlar filtration and folate,but not to methyl lenetrahy drofolate reductase and methionine syntheses polymor phisms,in supplemented end-stage renal disease patients Undergoing hemodialysis[J].Clin Chem Lab Med,2001,39(4):747-752.
[31]Peter WF.Homocysteine an dcoronary heart disease how great is the hazard?[J].JAMA,2002,288:2042-2043.
[32]丁少波,郑东文.慢性肾功能衰竭患者血浆同型半胱氨酸水平和血清叶酸、维生素B12的关系[J].中国医院药学杂志,2004,24(9):519-521.
[33]Tamaura T,Johnston KE,Bergman SM.J Am Soc Nephro,1996,(7):2414-2418.
[34]MoustaphaA,Gupta A,Robinson K,et al.Kidney Int,1999,55:1470-1475.
[35]Brulez HF,van Gluldener C,Donker A J,et al.Nephrol Dial Transplant,1999,14:154-159.
[36]Kimura H,Gijyo F,Suzuki S,et al.Am J Kidney Dis,2000,36(5):925-933.
[37]DucloxD,MotteG,LawsER,et al.Serum total homocysteine and car Diovascular disease occurrence in chronic stable renal transplant recipients,Aprospective study.[J].Am Soc Nephrol,2000,11:134-137.
[38]Chauveau P,Chadefaux B,Coude M,et al.Hyperhomocysteinemia,a risk factor for athero sclerosis in chronic uremic patients.[J].Kidney Int,1993,43(Supp 1141):S72-S77.
[39]Amadottir M,Win gren K,Hultber gB,et al.The postdialytic rise in the plasma total homocysteine concentration is delayed.BloodPurif,2002,20(4):334-337.
[40]陈朝生,徐玉兰,梅晓蓉,等.高通量血透对血浆同型半胱氨酸和超敏C反应蛋白的影响.中华肾脏病杂志,2006,22(8):506-507
[41]陈朝生,徐玉兰,梅晓蓉,等.长期高通量血透对血浆同型半胱氨酸及β2-微球蛋白和炎症因子的影响.中国中西医结合肾脏病杂志,2008,5(9):334-336.
[42]Moustapha A,Gupta A,Robinson K,et al.Prebalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.Kidney Int,1999,55:1470-1475.
[43]Vychytil A,fodinger M,Papagiannopoulos M,et al.Peritoneal elimination of monoeysteins moieties in continuous ambulatory peritoncal dialysis patients.Kidney Int,1999,55:2054-2061.
[44]Furchgott RF,Zawadski JF.The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine[J].Nature,1980,288:373-376.
[45]胡野,凌志强,单小云.细胞凋亡的分子医学.北京:军事医学科学出版社,2002:130-132.
[46]刘景生,细胞信息与调控.北京:北京医科大学中国协和医科大学联合出版社.1998:212-222.
[47]MCMICKING J,XIEQW,NATHAN C.Artnu REV Immunol,1997,15(3):323-328.
[48]CLANCG RM,AMIN AR,AHRAMSON SB,et al.Arthritis Rheum,1998,41(4):1141-1114.
[49]秦力铮,龙星.中华口腔医学杂志,2003,38(5):354.
[50]BIILAR T R.Am suIg,1995,221(4):339-349.
[51]MONCADA S,PALMER RM J,HIBBS JR,et al.Pharmacol Rev,1991,43(1):109-142.
[52]ANGGARD E.Lancet,1994,343(8907):1199-1206.
[53]Bravo J,Quiroz Y,Pons H,et al.Vimentin and heat shock Protein expression are induced in the kidney buy angiotensin and by nitric oxide inhibition[J].Kidney Int Supp 1,2003,10(86):46-51.
[54]ZHAOH,DNGAS N,MATHIOT C,et al.Blood,1998,92(3):1031-1043.
[55]Myatt L,Cui X.Oxidative stress in the placenta[J].Histochem Cell B iol,2004,122(4):369-382.
[56]Freeman SL,MacNaughton WK.Nitric oxide inhibitable isoforms of adenylate cyclase mediate epithelial secretory dysfunction following exposure to ionizing radiation[J].Gut,2004,53(2):214-221.
[57]Mattson DL,Wu F.Nitric oxide synthase activity and isoforms in the rat renal vasculature[J].Hypertension,2000,35(1Pt2):337-341.
[58]Ujiie K,Yuen J,Hogarth R,et al.Localization and regulation of endothelial NO synthase mRNA expression in rat kidney[J].Am J Physiol,1994,267(2Pt2):F296-F302.
[59]Kone BC,Chris B.Biosynthesis and homeostatic roles of nitric oxide in the normal kidney[J].Am J Physiol,1997,272(5Pt2):F561-F578.
[60]Vodovotz Y,Geiser AG,Chesler L,et al.Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforminggrowth factor betal null mouse[J].J Exp Med,1996,183(5):2337-2342.
[61]Taddei S,VirdisA,Mattei P,et al.Hypertension causes premature aging of endothelial function,in humans[J].Hypertension,1997,29(3):716-721.
[62]Robert MF,Wever,Pharm D,et al.Atherosclerosis and the two faces of endothelial nitric oxide synthase[J].Circulation,1998,97(6):108-111.
[63]Dusting GJ,Fennessy P,Zhang Li,et al.Nitric oxide in atherosclerosis:vascular protector or villain?[J].Clin Exp Pharmacol Physiol,1998,25(Suppl):S34-S41.
[64]Cantaro S,Milan Manani S.Marcon R.et al.Urinary excretion of vasoactive substances in chronic renal failure.Clin Nephorl,2001,55(5):393-399.
[65]Kartal Ozer N,Negis Y,Aytan N.Mechanisms of cholesterol or homocysteine effect in the depelopment of atherosclerosis:role of vitamin E[J].Biofactor,2003,19(1-2):63-70.
[66]Trachtman H,Futterweit S,Garg P,et al.Nitric oxide stimulated the activity of a 72 Kda neutral Matrix metalloproteininase in cultured rat mesangial cells.Biochem and Biophys Res Common,1996,218(3):704-708.
[67]黄颂敏,付平,李献等.L-精氨酸和一氧化氮对早期糖尿病大鼠肾小球高灌注的影响.华西医大学报,1997,28(3):251-254.
[68]张东亮,刘文虎,等.血液透析对ADMA的清除作用及NO生成的相关性研究.中国血液净化,2008,11(7):599-602.
[69]夏德全,魏锦兰.腹膜透析对尿毒症患者内皮素、一氧化氮的影响.临床荟萃,2001,14(16):997.
[1]Boushey CJ,Beresford SA,Imenn GS,et al.JAMA,1995,274:1049-1057.
[2]路建饶,武立群.老年慢性肾衰血液透析患者血浆同型半胱氨酸的临床研究[J].中国老年学杂志,2005,25:519-521.
[3]Pema AF,De Santo NG.lngrosso D Adverse effects of hyperhomocy steinemia and their managerment by folic acid[J].Miner Electrol Mctab,1997,23:174-178.
[4]Peter WF.Homocysteine an dcoronary heart.disease how great is the hazard?[J].JAMA,2002,288:2042-2043.
[5]余海峰,李春胜.慢性肾功能衰竭对血浆同型半胱氨酸水平的影响[J].实用医学杂志,2005,21(3):275-276.
[6]丁少波,郑东文.慢性肾功能衰竭患者血浆同型半胱氨酸水平和血清叶酸、维生素B_(12)的关系[J].中国医院药学杂志,2004,24(9):519-521.
[7]余月明,张明,侯凡凡,等.慢性肾功能衰竭病人高同型半胱氨酸血症及其影响因素[J].西南国防医药,2004,14(5):487-490.
[8]Tamaura T,.Johnston KE,Bergman SM.J Am Soc Nephro,1996,(7):2414-2418.
[9]Moustapha A,Gupta A,Robinson K,et al.Kidney Int,1999,55:1470-1475.
[10]Brulez HF,van Gluldener C,Donker A J,et al.Nephrol Dial Transplant,1999,14:154-159.
[11]Jacobsen DW.Cardiovascular disorders(risk assessment)[J].Clin Chem,1993,65:367-373.
[12]Boushey CJ,Beresfard SA,Omenn GS,et al.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increasing folic acid intakes[J].JAMA,1995,274(13):1049-1057.
[13]Graham IM,Daly LE,Refaum HM,et al.Plasma homocysteine as a risk factorfor vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
[14]Taylor LM Jr,DeFrang RD,Harris EJ Jr,et al.The association of elevated plasma homocyst(e)ine with progresion of symptomatic peripheral arterial disease[J].J Vase Surg,1991,13(1):128-136.
[15]Danesh J,LewingtonS.Plasma homocysteine and coronary artery disease:syste- matic review of published epidemiological studies[J].Cardiovasc Risk,1998,5:229-232.
[16]Nyord O,Vollest SE,Refaum H,et al.Total homocysteine and canliovascular disease[J].J Intern Med,1999,246:425-454.
[17]Meleady R,Graham I.Plasma homocysteine as a canliovascular riskfactor:causal,consequential,or of no consequence[J].Nutr Rev,1999,57:299-305.
[18]McCaddon A,Davies G,Hudson P,et al.Total serum homoeysteine in senile dementia of Alzheimer type[J].Int J Geriatr Psychiatry,1998,13(4):235-239.
[19]Fekkes D,van der Cammen TJ,van Loon CP,et al.Abnormal amino acid metabolism in patients with early stage Alzheimer dementia[J].J Neurat Transm,1998,105(2-3):287-294.
[20]Comes Trolin C,Regland B,Oreland L.Decreased methionine adenosyl transferase activity in erythrocytes of patients with dementia disorders[J].Eur Neuropsychopharmacol,1995,5(2):107-114.
[21]秦颖,祁金顺,乔健天.同型半胱氨酸与阿尔茨海默病[J].生理进展,2004,35:66-69.
[22]Krumdieck CL,Prince CW.Mechanisms of homocysteine toxicity on connective tissues:implications for the morbidity of aging[J].J Nutr,2000,230:365-368.
[23]Cuttomsen,Uelend PM,Svarstad E,et al.Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure[J].Kidney lnt,1997,52:459.
[24]高树生,陈竹钦.内皮素在妊高症发病中的作用[J].国外医学妇产科学分册,1993,20:330-333.
[25]Gao SS,Chert ZQ,Xu YQ.Plasma endothelin and atrial natriuretic peptide in nomal and hypertensive pregnancy[J].Chin Med J,1996,109:823-826.
[26]高树生,李黎,刘月旺,等.妊娠期口服叶酸对妊高症发病率的影响[J].现代妇产科学进展,2001,10:308-309.
[27]骆亚平,李敬东,李国选.血浆同型半胱氨酸水平与重症妊高症的关系[J].新乡医学院学报,2003,20:252-253.
[28]王鸿利.同型半胱氨酸的检测及其应用[J].诊断学理论与实践,2002,4:257-260.
[29]马连霞,葛音,张昭藩,等.同型半胱氨酸与2型糖尿病合并早期肾病及尿毒 症的关系[J].中国血液净化,2003,2:26-27.
[30]Bostom AG,Shrmin D,Lapane KL,et al.Hyper homocysteinemia and traditional cardiocascular diseae risk factors in end-stage renal diseade patients on dialysis case-contorl study.Atterrosclerosis,1995,114:93.
[31]Graham IM,Daly LE,Refsum HM,et al.JAMA,1997,277:1775-1781.
[32]Ridker PM,Manson JE,Buring JE,et al.JAMA,1999,281:1817-1821.
[33]Stampfer MJ,Malinow MR,Willett WC,et al.JAMA,1992,268-887.
[34]Moustapha A,Naso A,Nahlawi M,et al.Circulation,1998,97(2):138-141.
[35]Massy ZA,Ceballos I,Chadefaux-Vekemens B,et al.Kidney Int(Suppl),2001,78:243-245.
[36]Dalton ML,Gadson PF,Wrenn RW,et al.FASEB[J],1997,11:703-711.
[37]徐涛,王晓峰.B族维生素在肾移植受者高同型半胱氨酸血症及内皮功能异常治疗中的应用[J].中华外科杂志,2005,43(14):940-943.
[38]左力,王梅.维持性血液透析患者高同型半胱氨酸血症的影响因素和大剂量叶酸治疗的效果[J].中华肾脏病杂志,2002,18(5):327-330.
[39]Van Tellingen A,Grooteman MP,Ridgway EC,et al.Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients[J].Kidney Int,2001,59(1):342-347.
[40]Moustapha A,Gupta A,Robinson K,et al.Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.Kidney Int,1999,55:1470-1475.
[41]Vychytil A,fodinger M,Papagiannopoulos M,et al.Peritoneal elimination of monoeysteins moieties in continuous ambulatory peritoncal dialysis patients.Kidney Int,1999,55:2054-2061.
[42]Guttormsem AB,Ue jandPM.Svarslad E Kinetie basis of hyperhomocystinema in patients with chronic renal failure[J].Kindey Int,1997,52:495-520.
[43]Skoupy S,FodingerM,Ohno T,et al.Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients[J].J Am Soc Nephrol,2002,3(5):1331-1337.
[2]Boushey CJ,Beresfard SA,Omenn GS,et al.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increasing folic acid intakes[J].JAMA,1995,274(13):1049-1057.
[3]Graham IM,Daly LE,Refaum HM,et al.Plasma homocysteine as a risk factor for vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
[4]Taylor LM Jr,DeFrang RD,Harris EJ Jr,et al.The association of elevated plasma homocyst(e)ine with progresion of symptomatic peripheral arterial disease[J].Vase Surg,1991,13(1):128-136.
[5]Danesh J,LewingtonS.Plasma homocysteine and coronary artery disease:systematic review of published epidemiological studies[J].Cardiovasc Risk,1998,5:229-232.
[6]Nyord O,Vollest SE,Refaum H,et al.Total homocysteine and canliovascular disease[J].Intern Med,1999,246:425-454.
[7]Meleady R,Graham I.Plasma homocysteine as a canliovascular riskfactor:causal,consequential,or of no consequence[J].Nutr Rev,1999,57:299-305.
[8]Moustapha A,Naso A,Nahlawi M,et al.Circulation,1998,97(2):138-141.
[9]Rysz J,Luciak M,Kedziora J,et al.Nitric oxide release in peripheral blood during hemodialysis.Kidney Int,1997,51:294-300.
[10]Wever R,Boer P,Hjjmering M,et al.Nitric oxide production is reduced is patients with chronic renal failure.Arteroseler Thromb Vasc Biol,1999,19:1168-1172.
[11]路建饶,武立群.老年慢性肾衰血液透析患者血浆同型半胱氨酸的临床研究[J].中国老年学杂志,2005,25:519-521.
[12]Selhub J.Homocysteine metabolism[J].Annu Rev Med,1999,19:217-46.
[13]Hankey GJ,eikelboom JW,Ho WK,et al.Clinical usefulness of plasma homocyteine in vascular disease[J].Med J Aust,2004,181(6):314-318.
[14]Woo KS,Chook P,Lolin YI,et al.Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans[J].Circulation,1997,96(8):2542-2544.
[15]Faraci FM,Lentz SR.Hyperhomocysteinemla.oxidative stress,and cerebral vascular dysfunction.Stroke,2004,35:345-347.
[16]Lang D,Kredan MB,Moat AJ,et al.Homocysteine induced inhibitation of endothelium dependent relaxation in rabbit Aorta.Arterioscler Thromb Vase Biol,2000,20:422-427.
[17]Frank M,Steven R.Hyperhomocysteinemia,Oxidative Stress,and Cerebral Vascular-Dysfunction.Stroke,2004,35:345-347.
[18]Dayal S Arning E,Bottiglieri T,et al.Cerebral vascular Dysfunction mediated by superoxide in hyperhomocysteinmic mice[J].Stroke,2004,35:1957-1962.
[19]Neetu T,Kara C,Mesia S.et al.Mechanisms of homocysteine-induced oxidative stress[J].Am J Physiol Heart Cire Physiol,2005,289:H2649-H2656.
[20]Heydrick SJ,Wiesia N,Thomas SR et al.L-homocysteine and L-homocysteine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells[J].Free Radic Biol Med,2004,36:632-40.
[21]Toiler GH,Agoatino RB,Jacques PF,et al.Association between incrcasccl homocysteine levels and impaired fibrinolytic potential:potential mechanism for cardiovascular risk.Thromb Haemoat,2002,88:799-804.
[22]Majors AK,Sengupta S,Jacobsen DW,et al.Upregulation of smooth muscle cell collagen production by homocysteine insight into the pathogenesis of homocystinuria.Mol Genet Metab,2002,76(2):92-99.
[23]Kartal Ozer N,Negis Y,Aytan N.Molecular mechanisms of cholesterol or homocysteine efect in the development of atherosclerosis:Role of vitamin E.Biofactovs,2003,19(1-2):63-70.
[24]Au-Yetung KK,Woo CW,Sung FL,et al.Hyperhomoeysteinemia activates nuclear factor-κ B in endothelial cells via oxidative stress.Cite Res,2004,94:28-36.
[25]张红,张平,纪元.冠心病患者超敏C反应蛋白和同型半胱氨酸水平变化的意义[J].现代检验医学杂志,2007,22(6):102-103.
[26]郑法雷,章有康,陈香美,等.肾脏病临床与进展[J].北京:人民军医出版社,2005,239-257.
[27]Brattstom L,Wilcken DEL.Homocysteine and cardiovascular disease,cause or effect[J].Am J Clin Nutr,2000,72(2):315-323.
[28]邱丽君,顾青,汪维乐,等.尿毒症患者血浆同型半胱氨酸及皮细胞功能变化的意[J].检验医学,2008,23(2):143-144.
[29]余海峰,李春胜,陈军斌,等.慢性肾功能衰竭对血浆同型半胱氨酸水平的影响[J].实用医学杂志.2005,21(3):275-276.
[30]Anwar W,Gueant JL,Abdelmouttaleb,et al.Hyperhomocystemia is related to residual glomemlar filtration and folate,but not to methyl lenetrahy drofolate reductase and methionine syntheses polymor phisms,in supplemented end-stage renal disease patients Undergoing hemodialysis[J].Clin Chem Lab Med,2001,39(4):747-752.
[31]Peter WF.Homocysteine an dcoronary heart disease how great is the hazard?[J].JAMA,2002,288:2042-2043.
[32]丁少波,郑东文.慢性肾功能衰竭患者血浆同型半胱氨酸水平和血清叶酸、维生素B12的关系[J].中国医院药学杂志,2004,24(9):519-521.
[33]Tamaura T,Johnston KE,Bergman SM.J Am Soc Nephro,1996,(7):2414-2418.
[34]MoustaphaA,Gupta A,Robinson K,et al.Kidney Int,1999,55:1470-1475.
[35]Brulez HF,van Gluldener C,Donker A J,et al.Nephrol Dial Transplant,1999,14:154-159.
[36]Kimura H,Gijyo F,Suzuki S,et al.Am J Kidney Dis,2000,36(5):925-933.
[37]DucloxD,MotteG,LawsER,et al.Serum total homocysteine and car Diovascular disease occurrence in chronic stable renal transplant recipients,Aprospective study.[J].Am Soc Nephrol,2000,11:134-137.
[38]Chauveau P,Chadefaux B,Coude M,et al.Hyperhomocysteinemia,a risk factor for athero sclerosis in chronic uremic patients.[J].Kidney Int,1993,43(Supp 1141):S72-S77.
[39]Amadottir M,Win gren K,Hultber gB,et al.The postdialytic rise in the plasma total homocysteine concentration is delayed.BloodPurif,2002,20(4):334-337.
[40]陈朝生,徐玉兰,梅晓蓉,等.高通量血透对血浆同型半胱氨酸和超敏C反应蛋白的影响.中华肾脏病杂志,2006,22(8):506-507
[41]陈朝生,徐玉兰,梅晓蓉,等.长期高通量血透对血浆同型半胱氨酸及β2-微球蛋白和炎症因子的影响.中国中西医结合肾脏病杂志,2008,5(9):334-336.
[42]Moustapha A,Gupta A,Robinson K,et al.Prebalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.Kidney Int,1999,55:1470-1475.
[43]Vychytil A,fodinger M,Papagiannopoulos M,et al.Peritoneal elimination of monoeysteins moieties in continuous ambulatory peritoncal dialysis patients.Kidney Int,1999,55:2054-2061.
[44]Furchgott RF,Zawadski JF.The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine[J].Nature,1980,288:373-376.
[45]胡野,凌志强,单小云.细胞凋亡的分子医学.北京:军事医学科学出版社,2002:130-132.
[46]刘景生,细胞信息与调控.北京:北京医科大学中国协和医科大学联合出版社.1998:212-222.
[47]MCMICKING J,XIEQW,NATHAN C.Artnu REV Immunol,1997,15(3):323-328.
[48]CLANCG RM,AMIN AR,AHRAMSON SB,et al.Arthritis Rheum,1998,41(4):1141-1114.
[49]秦力铮,龙星.中华口腔医学杂志,2003,38(5):354.
[50]BIILAR T R.Am suIg,1995,221(4):339-349.
[51]MONCADA S,PALMER RM J,HIBBS JR,et al.Pharmacol Rev,1991,43(1):109-142.
[52]ANGGARD E.Lancet,1994,343(8907):1199-1206.
[53]Bravo J,Quiroz Y,Pons H,et al.Vimentin and heat shock Protein expression are induced in the kidney buy angiotensin and by nitric oxide inhibition[J].Kidney Int Supp 1,2003,10(86):46-51.
[54]ZHAOH,DNGAS N,MATHIOT C,et al.Blood,1998,92(3):1031-1043.
[55]Myatt L,Cui X.Oxidative stress in the placenta[J].Histochem Cell B iol,2004,122(4):369-382.
[56]Freeman SL,MacNaughton WK.Nitric oxide inhibitable isoforms of adenylate cyclase mediate epithelial secretory dysfunction following exposure to ionizing radiation[J].Gut,2004,53(2):214-221.
[57]Mattson DL,Wu F.Nitric oxide synthase activity and isoforms in the rat renal vasculature[J].Hypertension,2000,35(1Pt2):337-341.
[58]Ujiie K,Yuen J,Hogarth R,et al.Localization and regulation of endothelial NO synthase mRNA expression in rat kidney[J].Am J Physiol,1994,267(2Pt2):F296-F302.
[59]Kone BC,Chris B.Biosynthesis and homeostatic roles of nitric oxide in the normal kidney[J].Am J Physiol,1997,272(5Pt2):F561-F578.
[60]Vodovotz Y,Geiser AG,Chesler L,et al.Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforminggrowth factor betal null mouse[J].J Exp Med,1996,183(5):2337-2342.
[61]Taddei S,VirdisA,Mattei P,et al.Hypertension causes premature aging of endothelial function,in humans[J].Hypertension,1997,29(3):716-721.
[62]Robert MF,Wever,Pharm D,et al.Atherosclerosis and the two faces of endothelial nitric oxide synthase[J].Circulation,1998,97(6):108-111.
[63]Dusting GJ,Fennessy P,Zhang Li,et al.Nitric oxide in atherosclerosis:vascular protector or villain?[J].Clin Exp Pharmacol Physiol,1998,25(Suppl):S34-S41.
[64]Cantaro S,Milan Manani S.Marcon R.et al.Urinary excretion of vasoactive substances in chronic renal failure.Clin Nephorl,2001,55(5):393-399.
[65]Kartal Ozer N,Negis Y,Aytan N.Mechanisms of cholesterol or homocysteine effect in the depelopment of atherosclerosis:role of vitamin E[J].Biofactor,2003,19(1-2):63-70.
[66]Trachtman H,Futterweit S,Garg P,et al.Nitric oxide stimulated the activity of a 72 Kda neutral Matrix metalloproteininase in cultured rat mesangial cells.Biochem and Biophys Res Common,1996,218(3):704-708.
[67]黄颂敏,付平,李献等.L-精氨酸和一氧化氮对早期糖尿病大鼠肾小球高灌注的影响.华西医大学报,1997,28(3):251-254.
[68]张东亮,刘文虎,等.血液透析对ADMA的清除作用及NO生成的相关性研究.中国血液净化,2008,11(7):599-602.
[69]夏德全,魏锦兰.腹膜透析对尿毒症患者内皮素、一氧化氮的影响.临床荟萃,2001,14(16):997.
[1]Boushey CJ,Beresford SA,Imenn GS,et al.JAMA,1995,274:1049-1057.
[2]路建饶,武立群.老年慢性肾衰血液透析患者血浆同型半胱氨酸的临床研究[J].中国老年学杂志,2005,25:519-521.
[3]Pema AF,De Santo NG.lngrosso D Adverse effects of hyperhomocy steinemia and their managerment by folic acid[J].Miner Electrol Mctab,1997,23:174-178.
[4]Peter WF.Homocysteine an dcoronary heart.disease how great is the hazard?[J].JAMA,2002,288:2042-2043.
[5]余海峰,李春胜.慢性肾功能衰竭对血浆同型半胱氨酸水平的影响[J].实用医学杂志,2005,21(3):275-276.
[6]丁少波,郑东文.慢性肾功能衰竭患者血浆同型半胱氨酸水平和血清叶酸、维生素B_(12)的关系[J].中国医院药学杂志,2004,24(9):519-521.
[7]余月明,张明,侯凡凡,等.慢性肾功能衰竭病人高同型半胱氨酸血症及其影响因素[J].西南国防医药,2004,14(5):487-490.
[8]Tamaura T,.Johnston KE,Bergman SM.J Am Soc Nephro,1996,(7):2414-2418.
[9]Moustapha A,Gupta A,Robinson K,et al.Kidney Int,1999,55:1470-1475.
[10]Brulez HF,van Gluldener C,Donker A J,et al.Nephrol Dial Transplant,1999,14:154-159.
[11]Jacobsen DW.Cardiovascular disorders(risk assessment)[J].Clin Chem,1993,65:367-373.
[12]Boushey CJ,Beresfard SA,Omenn GS,et al.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increasing folic acid intakes[J].JAMA,1995,274(13):1049-1057.
[13]Graham IM,Daly LE,Refaum HM,et al.Plasma homocysteine as a risk factorfor vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
[14]Taylor LM Jr,DeFrang RD,Harris EJ Jr,et al.The association of elevated plasma homocyst(e)ine with progresion of symptomatic peripheral arterial disease[J].J Vase Surg,1991,13(1):128-136.
[15]Danesh J,LewingtonS.Plasma homocysteine and coronary artery disease:syste- matic review of published epidemiological studies[J].Cardiovasc Risk,1998,5:229-232.
[16]Nyord O,Vollest SE,Refaum H,et al.Total homocysteine and canliovascular disease[J].J Intern Med,1999,246:425-454.
[17]Meleady R,Graham I.Plasma homocysteine as a canliovascular riskfactor:causal,consequential,or of no consequence[J].Nutr Rev,1999,57:299-305.
[18]McCaddon A,Davies G,Hudson P,et al.Total serum homoeysteine in senile dementia of Alzheimer type[J].Int J Geriatr Psychiatry,1998,13(4):235-239.
[19]Fekkes D,van der Cammen TJ,van Loon CP,et al.Abnormal amino acid metabolism in patients with early stage Alzheimer dementia[J].J Neurat Transm,1998,105(2-3):287-294.
[20]Comes Trolin C,Regland B,Oreland L.Decreased methionine adenosyl transferase activity in erythrocytes of patients with dementia disorders[J].Eur Neuropsychopharmacol,1995,5(2):107-114.
[21]秦颖,祁金顺,乔健天.同型半胱氨酸与阿尔茨海默病[J].生理进展,2004,35:66-69.
[22]Krumdieck CL,Prince CW.Mechanisms of homocysteine toxicity on connective tissues:implications for the morbidity of aging[J].J Nutr,2000,230:365-368.
[23]Cuttomsen,Uelend PM,Svarstad E,et al.Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure[J].Kidney lnt,1997,52:459.
[24]高树生,陈竹钦.内皮素在妊高症发病中的作用[J].国外医学妇产科学分册,1993,20:330-333.
[25]Gao SS,Chert ZQ,Xu YQ.Plasma endothelin and atrial natriuretic peptide in nomal and hypertensive pregnancy[J].Chin Med J,1996,109:823-826.
[26]高树生,李黎,刘月旺,等.妊娠期口服叶酸对妊高症发病率的影响[J].现代妇产科学进展,2001,10:308-309.
[27]骆亚平,李敬东,李国选.血浆同型半胱氨酸水平与重症妊高症的关系[J].新乡医学院学报,2003,20:252-253.
[28]王鸿利.同型半胱氨酸的检测及其应用[J].诊断学理论与实践,2002,4:257-260.
[29]马连霞,葛音,张昭藩,等.同型半胱氨酸与2型糖尿病合并早期肾病及尿毒 症的关系[J].中国血液净化,2003,2:26-27.
[30]Bostom AG,Shrmin D,Lapane KL,et al.Hyper homocysteinemia and traditional cardiocascular diseae risk factors in end-stage renal diseade patients on dialysis case-contorl study.Atterrosclerosis,1995,114:93.
[31]Graham IM,Daly LE,Refsum HM,et al.JAMA,1997,277:1775-1781.
[32]Ridker PM,Manson JE,Buring JE,et al.JAMA,1999,281:1817-1821.
[33]Stampfer MJ,Malinow MR,Willett WC,et al.JAMA,1992,268-887.
[34]Moustapha A,Naso A,Nahlawi M,et al.Circulation,1998,97(2):138-141.
[35]Massy ZA,Ceballos I,Chadefaux-Vekemens B,et al.Kidney Int(Suppl),2001,78:243-245.
[36]Dalton ML,Gadson PF,Wrenn RW,et al.FASEB[J],1997,11:703-711.
[37]徐涛,王晓峰.B族维生素在肾移植受者高同型半胱氨酸血症及内皮功能异常治疗中的应用[J].中华外科杂志,2005,43(14):940-943.
[38]左力,王梅.维持性血液透析患者高同型半胱氨酸血症的影响因素和大剂量叶酸治疗的效果[J].中华肾脏病杂志,2002,18(5):327-330.
[39]Van Tellingen A,Grooteman MP,Ridgway EC,et al.Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients[J].Kidney Int,2001,59(1):342-347.
[40]Moustapha A,Gupta A,Robinson K,et al.Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.Kidney Int,1999,55:1470-1475.
[41]Vychytil A,fodinger M,Papagiannopoulos M,et al.Peritoneal elimination of monoeysteins moieties in continuous ambulatory peritoncal dialysis patients.Kidney Int,1999,55:2054-2061.
[42]Guttormsem AB,Ue jandPM.Svarslad E Kinetie basis of hyperhomocystinema in patients with chronic renal failure[J].Kindey Int,1997,52:495-520.
[43]Skoupy S,FodingerM,Ohno T,et al.Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients[J].J Am Soc Nephrol,2002,3(5):1331-1337.